NKTR 214

Drug Profile

NKTR 214

Alternative Names: NKTR214

Latest Information Update: 17 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nektar Therapeutics; University of Texas M. D. Anderson Cancer Center
  • Developer Bristol-Myers Squibb; Nektar Therapeutics; Takeda; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Cytokines
  • Mechanism of Action CD8 positive T lymphocyte stimulants; Immunostimulants; Interleukin-2 receptor beta subunit agonists; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Sarcoma
  • Phase I/II Bladder cancer; Colorectal cancer; Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours
  • Preclinical Lymphoma

Most Recent Events

  • 17 Nov 2017 Preclinical data for Cancer released by NausCom
  • 11 Nov 2017 Updated efficacy and adverse events data from the phase I/II PIVOT-02 trial in Solid tumours released by Nektar Therapeutics
  • 12 Sep 2017 Phase-II clinical trials in Sarcoma (Combination therapy) in USA (IV) (NCT03282344)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top